环孢菌素A单独或联合沙利度胺治疗骨髓增生异常综合征的临床效果研究  

Study on the clinical effects of cyclosporine A alone or in combination with thalidomide in the treatment of myelodysplastic syndrome

作　　者：邹鑫[1] ZOU Xin(Department of Hematology,Dalian Friendship Hospital,Dalian 116001,China)

机构地区：[1]大连市友谊医院血液科,116001

出　　处：《中国现代药物应用》2023年第17期144-146,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析环孢菌素A单独或联合沙利度胺治疗骨髓增生异常综合征的临床效果。方法52例骨髓增生异常综合征患者,随机分为对照组和治疗组,每组26例。对照组给予环孢菌素A单独治疗,治疗组给予环孢菌素A联合沙利度胺治疗。对比两组的红细胞改善情况、血小板改善情况及不良反应发生情况。结果治疗组红细胞改善显效25例,轻效1例,显效率为96.2%;对照组红细胞改善显效20例,轻效6例,显效率为76.9%。治疗组红细胞改善显效率高于对照组,差异有统计学意义(P<0.05)。治疗组血小板改善显效24例,轻效2例,显效率为92.3%;对照组血小板改善显效18例,轻效8例,显效率为69.2%。治疗组血小板改善显效率高于对照组,差异有统计学意义(P<0.05)。治疗组不良反应发生率为7.7%,与对照组的15.4对比,差异无统计学意义(P>0.05)。结论针对骨髓增生异常综合征患者,采取环孢菌素A联合沙利度胺治疗优势明显,能最大程度的缓解临床不良反应,促进患者恢复,因此联合治疗方式值得推广和实施。Objective To analyze the clinical effects of cyclosporine A alone or in combination with thalidomide in the treatment of myelodysplastic syndrome.Methods A total of 52 patients with myelodysplastic syndrome were randomly divided into control group and treatment group,with 26 cases in each group.The control group was treated with cyclosporin A alone,and the treatment group was treated with cyclosporin A and thalidomide.The improvement of red blood cell and platelet,and adverse reactions were compared between the two groups.Results In the treatment group,25 cases showed significant improvement in red blood cells and 1 case showed mild improvement,with a significant efficiency of 96.2%;in the control group,20 cases showed significant improvement in red blood cells and 6 cases showed mild improvement,with a significant efficiency of 76.9%.The improvement efficiency of red blood cells in the treatment group was higher than that in the control group,and the difference was statistically significant(P<0.05).In the treatment group,there were 24 cases with obvious platelet improvement and 2 cases with mild effect,the significant efficiency was 92.3%;in the control group,there were 18 cases with obvious platelet improvement and 8 cases with mild effect,the significant efficiency was 69.2%.The improvement efficiency of platelet in the treatment group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the treatment group was 7.7%,and the difference was not statistically significant when compared with that of 15.4%in the control group(P>0.05).Conclusion For patients with myelodysplastic syndrome,the combination of cyclosporin A and thalidomide has obvious advantages,which can alleviate clinical adverse reactions to the greatest extent and promote patient recovery.Therefore,the combination therapy is worth promoting and implementing.

关 键 词：环孢菌素A 沙利度胺 骨髓增生异常综合征 效果 

分 类 号：R551.3[医药卫生—血液循环系统疾病]